摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-[(dimethylamino)methyl]-7,8-dihydro-2-naphthalenamine | 331760-35-1

中文名称
——
中文别名
——
英文名称
6-[(dimethylamino)methyl]-7,8-dihydro-2-naphthalenamine
英文别名
6-[(N,N-dimethylamino)methyl]-7,8-dihydro-2-naphthaleneamine;6-[(N,N-Dimethylamino)methyl]-7,8-dihydro-2-naphthalenamine;6-[(dimethylamino)methyl]-7,8-dihydronaphthalen-2-amine
6-[(dimethylamino)methyl]-7,8-dihydro-2-naphthalenamine化学式
CAS
331760-35-1
化学式
C13H18N2
mdl
——
分子量
202.299
InChiKey
TWPLWCXWCQSEAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery, synthesis, and structure–activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists
    摘要:
    Human melanin-concentrating hormone receptor 1 (hMCHR1) antagonists are promising targets for obesity treatment. We identified the tetrahydronaphthalene derivative 1a with modest binding affinity for hMCHR1 by screening an in-house G protein-coupled receptor (GPCR) ligand library. We synthesized a series of 6-aminomethyl-5,6,7,8-tetrahydronaphthalenes and evaluated their activity as hMCHR1 antagonists. Modification of the biphenylcarbonylamino group revealed that the biphenyl moiety played a crucial role in the interaction of the antagonist with the receptor. The stereoselective effect of the chiral center on binding affinity generated the novel 6-aminomethyl-7,8-dihydronaphthalene scaffold without a chiral center. Optimization of the amino group led to the identification of a potent antagonist 2s (4'-fluoro-N[6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide), which significantly inhibited the nocturnal food intake in rats after oral administration. Pharmacokinetic analysis confirmed that 2s had good oral bioavailability and brain penetrance. This antagonist appears to be a viable lead compound that can be used to develop a promising therapy for obesity. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.07.038
  • 作为产物:
    描述:
    参考文献:
    名称:
    Melanin concentrating hormone antagonist
    摘要:
    一种黑色素浓缩激素拮抗剂,包括以下式的化合物: 其中Ar1是可能具有取代基团的环状基团; X是具有1到6个原子的主链的间隔物; Y是键或具有1到6个原子的主链的间隔物; Ar是可能与4到8个成员的非芳香环融合的单环芳香环,并且可能具有进一步的取代基团; R1和R2分别是氢原子或可能具有取代基团的碳氢基团;R1和R2,连同相邻的氮原子,可能形成可能具有取代基团的含氮杂环;R2可能与Ar一起形成螺环;或者R2,连同相邻的氮原子和Y,可能形成可能具有取代基团的含氮杂环;或其盐; 该化合物可用作预防或治疗肥胖等疾病的药剂。
    公开号:
    US07115750B1
点击查看最新优质反应信息

文献信息

  • 6-(4-Chlorophenyl)-3-substituted-thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist
    作者:Francis X. Tavares、Kamal A. Al-Barazanji、Michael J. Bishop、Christy S. Britt、David L. Carlton、Joel P. Cooper、Paul L. Feldman、Dulce M. Garrido、Aaron S. Goetz、Mary K. Grizzle、Donald L. Hertzog、Diane M. Ignar、Daniel G. Lang、Maggie S. McIntyre、Ronda J. Ott、Andrew J. Peat、Hui-Qiang Zhou
    DOI:10.1021/jm060814b
    日期:2006.11.30
    Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.
  • MELANIN CONCENTRATING HORMONE ANTAGONIST
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1218336A2
    公开(公告)日:2002-07-03
  • US7115750B1
    申请人:——
    公开号:US7115750B1
    公开(公告)日:2006-10-03
  • [EN] MELANIN CONCENTRATING HORMONE ANTAGONIST<br/>[FR] ANTAGONISTE DE L'HORMONE DE CONCENTRATION DE LA MELANINE
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2001021577A2
    公开(公告)日:2001-03-29
    A melanin-concentrating hormone antagonist which comprises a compound of formula (I) wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R?1 and R2¿ are independently hydrogen atom or a hydrocarbon group which may have substituents; R?1 and R2¿, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.
  • Discovery, synthesis, and structure–activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists
    作者:Makoto Kamata、Toshiro Yamashita、Toshihiro Imaeda、Toshio Tanaka、Jun Terauchi、Maki Miyamoto、Taiichi Ora、Michiko Tawada、Satoshi Endo、Shiro Takekawa、Asano Asami、Nobuhiro Suzuki、Yasutaka Nagisa、Yoshihide Nakano、Kaoru Watanabe、Hitomi Ogino、Koki Kato、Kaneyoshi Kato、Yuji Ishihara
    DOI:10.1016/j.bmc.2011.07.038
    日期:2011.9
    Human melanin-concentrating hormone receptor 1 (hMCHR1) antagonists are promising targets for obesity treatment. We identified the tetrahydronaphthalene derivative 1a with modest binding affinity for hMCHR1 by screening an in-house G protein-coupled receptor (GPCR) ligand library. We synthesized a series of 6-aminomethyl-5,6,7,8-tetrahydronaphthalenes and evaluated their activity as hMCHR1 antagonists. Modification of the biphenylcarbonylamino group revealed that the biphenyl moiety played a crucial role in the interaction of the antagonist with the receptor. The stereoselective effect of the chiral center on binding affinity generated the novel 6-aminomethyl-7,8-dihydronaphthalene scaffold without a chiral center. Optimization of the amino group led to the identification of a potent antagonist 2s (4'-fluoro-N[6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide), which significantly inhibited the nocturnal food intake in rats after oral administration. Pharmacokinetic analysis confirmed that 2s had good oral bioavailability and brain penetrance. This antagonist appears to be a viable lead compound that can be used to develop a promising therapy for obesity. (C) 2011 Elsevier Ltd. All rights reserved.
查看更多